Search results
Results from the WOW.Com Content Network
GW-405,833 (L-768,242) is a drug that acts as a potent and selective partial agonist for the cannabinoid receptor subtype CB 2, with an EC 50 of 0.65 nM and selectivity of around 1200x for CB 2 over CB 1 receptors.
Studies have revealed the specific connection between infection-trigger and disease onset in a cohort of chronic fatigue syndrome patients. These patients showed significantly elevated antibodies to beta2-adrenergic receptors. Future research solidifying this correlation of CFS with autoantibodies to adrenergic receptors would be useful to ...
Lymphocyte-activation gene 3, also known as LAG-3, is a protein which in humans is encoded by the LAG3 gene. [5] LAG3, which was discovered in 1990 [6] and was designated CD223 (cluster of differentiation 223) after the Seventh Human Leucocyte Differentiation Antigen Workshop in 2000, [7] is a cell surface molecule with diverse biological effects on T cell function but overall has an immune ...
Eftilagimod alpha ("efti" in short) is a soluble LAG-3 fusion protein that activates antigen-presenting cells.It is a 160 kDa protein consisting of the four extracellular domains of LAG-3 fused to the Fc region of an IgG1(LAG-3Ig).
The first approved medication in this class, tocilizumab (Actemra), is an antibody directed against the IL6-receptor. [8] The second, siltuximab (Sylvant), is directed against IL-6 itself. [ 1 ] [ 9 ] Siltuximab is approved for treatment of human immunodeficiency virus-negative and HHV-8 -negative patients with multicentric Castleman's disease .
SR144528 is a drug that acts as a potent and highly selective CB 2 receptor inverse agonist, with a K i of 0.6 nM at CB 2 and 400 nM at the related CB 1 receptor.
Faricimab is a 150kDa-sized bispecific antibody whose molecular structure allows a high affinity bond to both vascular endothelial growth factor A (VEGF-A) and Angiopoietin (Ang-2). [9] By blocking the action of these two growth factors, faricimab decreases migration and replication of endothelial cells allowing for stabilization of vascular ...
L-759,656 is an analgesic drug that is a cannabinoid agonist.It is a highly selective agonist for the CB 2 receptor, with selectivity of 414x for CB 2 over CB 1, [1] although it is still not as selective as newer agents such as HU-308.